99Tc labled Inliximab for evaluation of inflammatory activity in patients with inflammtory bowel disease (IBD)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-000842-11-AT

Enrollment

Unknown

Registered

2007-09-04

Start date

2007-10-15

Completion date

Unknown

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease Crohn´s disease Ulcerative colitis

Interventions

Pharmaceutical Form: Intravenous infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277313

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: active inflammatory bowel disease age over 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: immune deficiency, allergy to infliximab, malignancy, severe infections, pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: Comparison of szintigraphy using 99Tc labled infliximab for evaulation of inflammatory activity in patients with IBD inflammation seen by routine endoscopy ;Secondary Objective: ;Primary end point(s): Comparison of szintigraphy using 99Tc labled infliximab for evaulation of inflammatory activity and localisation in patients with active IBD. Results will be compared to inflammation seen by routine endoscopy.	—

Measure

Time frame

Main Objective: Comparison of szintigraphy using 99Tc labled infliximab for evaulation of inflammatory activity in patients with IBD inflammation seen by routine endoscopy ;Secondary Objective: ;Primary end point(s): Comparison of szintigraphy using 99Tc labled infliximab for evaulation of inflammatory activity and localisation in patients with active IBD. Results will be compared to inflammation seen by routine endoscopy.

—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026